Sweden-based Medivir – which in October 2016 decided to only focus on oncology R&D – is divesting its research stage metallo-β-lactamase inhibitor (MBLI) program to the UK's AMR Centre Ltd in return for a proportion of future sales from antimicrobials produced.
The MBLI program is aimed at tackling the threat posed by NDM-1 and other metallo-β-lactamases, enzymes that make bacteria resistant...








